TABLE 3.
Matched bivariate analysis
| Characteristicd | Patients with an eCrCL of: |
P valuee | |
|---|---|---|---|
| <30 ml/min (n = 40) | ≥30 ml/min (n = 40) | ||
| Baseline demographics and treatment information | |||
| Age (median [IQR] [yrs]) | 80 (63.8–89) | 84 (70.8–87.5) | 0.554a |
| Female gender (no. [%]) | 23 (57.5) | 18 (45) | 0.263b |
| Body mass index of >30 kg/m2 (no. [%]) | 14 (35) | 16 (40) | 0.644b |
| Cirrhosis (no. [%]) | 2 (5) | 0 (0) | 0.494c |
| Diabetes mellitus (no. [%]) | 24 (60) | 12 (30) | 0.007b |
| Heart failure (no. [%]) | 18 (45) | 6 (15) | 0.003b |
| Hypertension (no. [%]) | 34 (85) | 29 (72.5) | 0.172c |
| Renal transplant (no. [%]) | 1 (2.5) | 0 (0) | >0.999c |
| Baseline SCr (median [IQR] [mg/dl]) | 1.2 (1–2.1) | 0.85 (0.7–1) | <0.001a |
| SCr (mg/dl) on the day of remdesivir administration (median [IQR]) | 2.8 (1.6–4.2) | 0.9 (0.8–1.3) | <0.001a |
| CrCl (ml/min) on the day of remdesivir administration by C-G (median [IQR]) | 20.3 (15.3–26.3) | 51.3 (38.3–66.6) | <0.001a |
| eGFR (ml/min/1.73 m2) on the day of remdesivir administration by MDRD (median [IQR]) | 21 (15.2–34.1) | 73.6 (53.8–93.9) | <0.001a |
| ALT > 5× ULN on the first day of remdesivir administration | 0.494c | ||
| Total no. | 40 | 39 | |
| No. (%) | 2 (5) | 0 (0) | |
| In AKI on the day of remdesivir administration (no. [%]) | 16 (40) | 6 (15) | 0.012b |
| Vasopressor or inotrope use during remdesivir (no. [%]) | 12 (30) | 8 (20) | 0.302a |
| Mechanical ventilation during remdesivir (no. [%]) | 11 (27.5) | 8 (20) | 0.431b |
| Concomitant nephrotoxic drug (no. [%]) | |||
| Vancomycin | 5 (12.5) | 9 (22.5) | 0.239c |
| Aminoglycoside | 1 (2.5) | 0 (0) | >0.999c |
| i.v. acyclovir | 1 (2.5) | 0 (0) | >0.999c |
| TMP-SMX | 0 (0) | 0 (0) | >0.999c |
| Amphotericin B | 0 (0) | 0 (0) | >0.999c |
| ACE/ARB | 8 (20) | 8 (20) | >0.999c |
| Loop/thiazide diuretics | 24 (60) | 15 (37.5) | 0.04b |
| Tacrolimus/cyclosporine | 1 (2.5) | 0 (0) | >0.999c |
| i.v. contrast | 3 (7.5) | 7 (17.5) | 0.311c |
| NSAIDS | 0 (0) | 1 (2.5) | >0.999c |
| Days of remdesivir treatment (median [IQR]) | 5 (4–5) | 5 (4–5) | 0.782a |
| Safety outcomes | |||
| AKI using EOT SCr (no. [%]) | 2 (5) | 1 (2.5) | >0.999c |
| AKI using peak SCr (no. [%]) | 2 (5) | 1 (2.5) | >0.999c |
| ALT > 5× ULN on last day of remdesivir | 0.49c | ||
| Total no. | 38 | 38 | |
| No. (%) | 0 (0) | 2 (5.3) | |
| Remdesivir discontinued early due to abnormal LFTs (no. [%]) | 0 (0) | 2 (5) | 0.494c |
| 30-day mortality | 0.029b | ||
| Total no. | 34 | 31 | |
| No. (%) | 19 (55.9) | 9 (29) | |
a
Mann-Whitney U test.
b
Chi-square test.
c
Fisher’s exact test.
d
C-G, Cockgrauft-Gault equation; MDRD, modification of diet in renal disease; TMP-SMX, trimethoprim-sulfamethoxazole; ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blocker; NSAIDS, nonsteroidal anti-inflammatory drugs; SCr, serum creatinine; LFTs, liver function tests.
eBolded values are P < 0.05.